3 results
Approved WMORecruiting
The overall aim of this study is to demonstrate increase of tumor-infiltrating CD8+ T cells in non-small cell lung cancer during neo-adjuvant treatment with durvalumab (MEDI4736).
Approved WMORecruiting
Our primary objective is to assess the differences in the incidence of short term complications (wound infection, wound breakdown and lymphocele) after IFL using LigaSure versus the conventional method. Furthermore, we will assess the differences in…
Approved WMOPending
To compare ACM at Day 42 following treatment with olorofim versus treatment with AmBisome® followed by SOC in the intent-to-treat (ITT) population of patients with IFD caused by proven IA at any site or probable lower respiratory tract disease (LRTD…